{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:06:22Z","timestamp":1788303982816,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004332","name":"Seoul National University Hospital","doi-asserted-by":"publisher","award":["02-2016-0430"],"award-info":[{"award-number":["02-2016-0430"]}],"id":[{"id":"10.13039\/501100004332","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004332","name":"Seoul National University Hospital","doi-asserted-by":"publisher","award":["25-2014-0040"],"award-info":[{"award-number":["25-2014-0040"]}],"id":[{"id":"10.13039\/501100004332","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea (NRF)","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Ministry of Science, ICT & Future Planning, Republic of Korea","award":["2016R1C1B2011815"],"award-info":[{"award-number":["2016R1C1B2011815"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.jneuroim.2016.09.001","type":"journal-article","created":{"date-parts":[[2016,9,9]],"date-time":"2016-09-09T12:52:47Z","timestamp":1473425567000},"page":"107-111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"special_numbering":"C","title":["New feasible treatment for refractory autoimmune encephalitis: Low-dose interleukin-2"],"prefix":"10.1016","volume":"299","author":[{"given":"Jung-Ah","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soon-Tae","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jangsup","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Sun","family":"Jun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byeong-su","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Ick","family":"Byun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Sang","family":"Sunwoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Il","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keun-Hwa","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki-Young","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Kun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kon","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2016.09.001_bb0005","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/WCO.0000000000000087","article-title":"Autoimmune encephalitis as differential diagnosis of infectious encephalitis","volume":"27","author":"Armangue","year":"2014","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.jneuroim.2016.09.001_bb0010","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/nri3156","article-title":"The role of interleukin-2 during homeostasis and activation of the immune system","volume":"12","author":"Boyman","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jneuroim.2016.09.001_bb0015","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/nri2889","article-title":"Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases","volume":"10","author":"Buckner","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jneuroim.2016.09.001_bb0020","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jneuroim.2016.02.002","article-title":"Prevalence of antineuronal antibodies in patients with encephalopathy of unknown etiology: data from a nationwide registry in Korea","volume":"293","author":"Byun","year":"2016","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2016.09.001_bb0025","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/nm.3411","article-title":"Regulatory T cell proliferative potential is impaired in human autoimmune disease","volume":"20","author":"Carbone","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.jneuroim.2016.09.001_bb0030","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1001\/jamadermatol.2014.504","article-title":"Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata","volume":"150","author":"Castela","year":"2014","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.jneuroim.2016.09.001_bb0035","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S1474-4422(08)70224-2","article-title":"Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies","volume":"7","author":"Dalmau","year":"2008","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneuroim.2016.09.001_bb0040","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S1474-4422(10)70253-2","article-title":"Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis","volume":"10","author":"Dalmau","year":"2011","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneuroim.2016.09.001_bb0045","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jneuroim.2006.09.012","article-title":"Interferon beta-1a therapy enhances CD4+ regulatory T-cell function: an ex vivo and in vitro longitudinal study in relapsing-remitting multiple sclerosis","volume":"182","author":"de Andres","year":"2007","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2016.09.001_bb0050","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","article-title":"A clinical approach to diagnosis of autoimmune encephalitis","volume":"15","author":"Graus","year":"2016","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneuroim.2016.09.001_bb0055","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.4049\/jimmunol.179.2.1322","article-title":"Prevalence of newly generated naive regulatory T cells (Treg) is critical for Treg suppressive function and determines Treg dysfunction in multiple sclerosis","volume":"179","author":"Haas","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.jneuroim.2016.09.001_bb0060","doi-asserted-by":"crossref","DOI":"10.1038\/nm.4148","article-title":"Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus","author":"He","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.jneuroim.2016.09.001_bb0065","doi-asserted-by":"crossref","first-page":"6449","DOI":"10.1073\/pnas.0502187102","article-title":"Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3","volume":"102","author":"Hong","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jneuroim.2016.09.001_bb0070","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1136\/annrheumdis-2014-206506","article-title":"Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE","volume":"74","author":"Humrich","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jneuroim.2016.09.001_bb0075","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/nri3823","article-title":"The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases","volume":"15","author":"Klatzmann","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jneuroim.2016.09.001_bb0080","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1056\/NEJMoa1108188","article-title":"Interleukin-2 and regulatory T cells in graft-versus-host disease","volume":"365","author":"Koreth","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2016.09.001_bb0085","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1474-4422(09)70324-2","article-title":"Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen","volume":"9","author":"Lancaster","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneuroim.2016.09.001_bb0090","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1212\/WNL.0000000000002635","article-title":"Rituximab treatment for autoimmune limbic encephalitis in an institutional cohort","volume":"86","author":"Lee","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2016.09.001_bb0095","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.immuni.2013.01.004","article-title":"Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy","volume":"38","author":"Liao","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.jneuroim.2016.09.001_bb0100","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1146\/annurev.immunol.26.021607.090357","article-title":"The biology of interleukin-2","volume":"26","author":"Malek","year":"2008","journal-title":"Annu. Rev. Immunol."},{"issue":"Suppl 1","key":"10.1016\/j.jneuroim.2016.09.001_bb0105","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1007\/s10875-008-9176-5","article-title":"Primary immune deficiency disorders presenting as autoimmune diseases: IPEX and APECED","volume":"28","author":"Moraes-Vasconcelos","year":"2008","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.jneuroim.2016.09.001_bb0110","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.smim.2003.12.003","article-title":"Naturally-occurring CD4+CD25+ immunoregulatory T cells: central players in the arena of peripheral tolerance","volume":"16","author":"Piccirillo","year":"2004","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.jneuroim.2016.09.001_bb0115","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1056\/NEJMoa1105143","article-title":"Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis","volume":"365","author":"Saadoun","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2016.09.001_bb0120","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.cell.2008.05.009","article-title":"Regulatory T cells and immune tolerance","volume":"133","author":"Sakaguchi","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.jneuroim.2016.09.001_bb0125","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1474-4422(12)70310-1","article-title":"Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study","volume":"12","author":"Titulaer","year":"2013","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneuroim.2016.09.001_bb0130","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1182\/blood-2014-07-587493","article-title":"Interleukin-5-producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapy","volume":"124","author":"Van Gool","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jneuroim.2016.09.001_bb0135","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jneuroim.2009.08.007","article-title":"Interferon-beta-1a treatment increases CD56bright natural killer cells and CD4+CD25+ Foxp3 expression in subjects with multiple sclerosis","volume":"215","author":"Vandenbark","year":"2009","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2016.09.001_bb0140","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1084\/jem.20031579","article-title":"Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis","volume":"199","author":"Viglietta","year":"2004","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jneuroim.2016.09.001_bb0145","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.immuni.2008.11.014","article-title":"A low interleukin-2 receptor signaling threshold supports the development and homeostasis of T regulatory cells","volume":"30","author":"Yu","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.jneuroim.2016.09.001_bb0150","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1136\/jnnp-2011-301237","article-title":"Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognition","volume":"83","author":"Zuliani","year":"2012","journal-title":"J. Neurol. Neurosurg. Psychiatry"}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572816302442?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572816302442?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:28:41Z","timestamp":1759048121000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572816302442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":30,"alternative-id":["S0165572816302442"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2016.09.001","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New feasible treatment for refractory autoimmune encephalitis: Low-dose interleukin-2","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2016.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}